首页> 美国卫生研究院文献>Theranostics >Inhibition of HSP90β Improves Lipid Disorders by Promoting Mature SREBPs Degradation via the Ubiquitin-proteasome System
【2h】

Inhibition of HSP90β Improves Lipid Disorders by Promoting Mature SREBPs Degradation via the Ubiquitin-proteasome System

机译:HSP90β的抑制通过泛素-蛋白酶体系统促进成熟的SREBPs降解而改善脂质紊乱

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Rationale: Heat shock protein 9 (HSP90) are a family of the most highly expressed cellular proteins and attractive drug targets against cancer, neurodegeneration diseases, etc. HSP90 proteins have also been suggested to be linked to lipid metabolism. However, the specific function of HSP90 paralogs, as well as the underlying molecular cascades remains largely unknown. This study aims to unravel the paralog-specific role of HSP90 in lipid metabolism and try to discover paralog-specific HSP90 inhibitors.>Methods: In non-alcohol fatty liver disease (NAFLD) patients, as well as in diet induced obese (DIO) mice, expression of HSP90 paralogs were analyzed by immunohistochemistry and western blot. In hepatocytes and in DIO mice, HSP90 proteins were knockdown by siRNAs/shRNAs, metabolic parameters, as well as downstream signaling were then investigated. By virtue screening, corylin was found to bind specifically to HSP90β. Using photo-affinity labeling and mass spectrum, corylin binding proteins were identified. After oral administration of corylin, its lipid lowering effects in different metabolic disease mice models were evaluated.>Results: We showed that hepatic HSP90β, rather than HSP90α, was overexpressed in NAFLD patients and obese mice. Hepatic HSP90β was also clinical relevant to serum lipid level. Depletion of HSP90β promoted mature sterol regulatory element-binding proteins (mSREBPs) degradation through Akt-GSK3β-FBW7 pathway, thereby dramatically decreased the content of neutral lipids and cholesterol. We discovered an HSP90β-selective inhibitor (corylin) that only bound to its middle domain. We found that corylin treatment partially suppressed Akt activity only at Thr308 site and specifically promoted mSREBPs ubiquitination and proteasomal degradation. Corylin treatment significantly reduced lipid content in both liver cell lines and human primary hepatocytes. In animal studies, we showed that corylin ameliorated obesity-induced fatty liver disease, type 2 diabetes and atherosclerosis.>Principle conclusions: HSP90β plays a parolog-specific role in regulating lipid homeostasis. Compound that selectively inhibits HSP90β could be useful in the clinic for the treatment for metabolic diseases.
机译:>原理:热休克蛋白9(HSP90)是表达最强的细胞蛋白家族,是针对癌症,神经退行性疾病等的有吸引力的药物靶标。HSP90蛋白也被认为与脂质代谢有关。但是,HSP90旁系同源物的具体功能以及潜在的分子级联作用仍然未知。这项研究旨在揭示HSP90在脂类代谢中特定于同源物的作用,并试图发现特定于HSP90的同源物。>方法:在非酒精性脂肪性肝病(NAFLD)患者以及非酒精性脂肪肝患者中饮食诱导的肥胖(DIO)小鼠,通过免疫组织化学和免疫印迹分析HSP90旁系同源物的表达。在肝细胞和DIO小鼠中,通过siRNA / shRNA敲低HSP90蛋白,然后研究代谢参数以及下游信号传导。通过筛选,发现corylin与HSP90β特异性结合。使用光亲和标记和质谱,鉴定出corylin结合蛋白。口服Corylin后,评估了其在不同代谢疾病小鼠模型中的降脂作用。>结果:我们显示,NAFLD患者和肥胖小鼠肝HSP90β而非HSP90α过表达。肝HSP90β在临床上也与血脂水平有关。 HSP90β的耗竭通过Akt-GSK3β-FBW7途径促进了成熟的固醇调节元件结合蛋白(mSREBPs)降解,从而显着降低了中性脂质和胆固醇的含量。我们发现了仅结合其中间结构域的HSP90β选择性抑制剂(corylin)。我们发现corylin治疗仅在Thr308位点部分抑制了Akt活性,并特别促进了mSREBPs的泛素化和蛋白酶体降解。 Corylin治疗显着降低了肝细胞系和人原代肝细胞中的脂质含量。在动物研究中,我们发现corylin改善了肥胖引起的脂肪肝疾病,2型糖尿病和动脉粥样硬化。>原理结论:HSP90β在调节脂质体内平衡方面具有类似的作用。选择性抑制HSP90β的化合物可能在临床上可用于治疗代谢性疾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号